Tamper-Resistant Opioid Dosage Form via Gel Viscosity

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current pharmaceutical dosage forms for opioid analgesics are vulnerable to tampering and abuse, particularly parenteral and nasal abuse, as they can be crushed or dissolved for illicit use, and existing solutions rely heavily on antagonist inclusion to deter misuse.

Innovation Solution

An immediate release solid oral dosage form comprising particles with a core of gelling agent, a barrier layer, and an active layer, where the barrier layer is made of hydroxypropylmethylcellulose, polyvinyl alcohol, or povidone, preventing drug absorption through high viscosity when mixed with liquid, thereby reducing tampering and abuse potential.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Speed

If an opioid analgesic is formulated for immediate release, then rapid pain relief is achieved, but the formulation becomes susceptible to crushing and parenteral abuse

Engineering Contradiction:
Improvedrug release speedVSAvoidabuse potential
Core Design Contradiction:
SpeedVSObject-affected harmful factors

Solution Approach 1:

The dosage form is divided into multiple particles or granules, each containing the opioid analgesic. This segmentation maintains immediate release properties while making the formulation less susceptible to complete crushing and extraction, as the dispersed particles are more difficult to process for illicit use compared to a single intact tablet or capsule.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The opioid analgesic is combined with specific excipients or formulation materials that create a composite structure. This composite material maintains rapid dissolution and absorption for therapeutic effect while providing physical or chemical properties that deter crushing, extraction, or other tampering attempts for parenteral abuse.

Inventive Principle:
Principle #40Composite materials

2Reliability

If a barrier layer is added to prevent abuse, then tamper resistance is improved, but manufacturing complexity increases

Engineering Contradiction:
Improvetamper resistanceVSAvoiddosage form structure
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

Instead of creating a complex multi-layer barrier structure, the formulation applies tamper-resistant properties locally through the selection of specific excipients or materials mixed with the opioid analgesic. This local approach provides abuse deterrence without requiring complex layered structures, maintaining manufacturing simplicity while achieving the desired reliability.

Inventive Principle:
Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The dosage form achieves rapid drug release while significantly hindering parenteral and nasal absorption, providing a tamper-resistant formulation that maintains effective plasma levels and reduces abuse potential.

Implementation Method 1

An immediate release solid oral dosage form comprising particles with a core of gelling agent

Methodology Applied
Scientific EffectGel formation: Gel

Implementation Method 2

preventing drug absorption through high viscosity when mixed with liquid

Methodology Applied
Scientific EffectViscosity increase: Viscometer

Implementation Method 3

a barrier layer, made of hydroxypropylmethylcellulose, polyvinyl alcohol, or povidone, preventing drug absorption

Methodology Applied
Scientific EffectPhysical barrier: Physical Containment

Data Source

PatentEP3078370B1Tamper resistant immediate release formulations
Publication Date: 2018.11.07 PURDUE PHARMA LP
  • EP3078370B1 patent drawingFigure 1

AI summary

Disclosed in certain embodiments is an oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising a gelling agent; (ii) an optional barrier layer encompassing the core; (iii) an active layer comprising a drug susceptible to abuse encompassing the core or barrier layer; and (iv) an optional controlled release excipient; wherein the dosage form provides an immediate or controlled release; and wherein the viscosity of the dosage form mixed with from about 0.5 to about 10 ml of an aqueous liquid is unsuitable for parenteral or nasal administration.